Ziprasidone
Ziprasidone. Atypical antipsychotic; potent D2 / 5-HT2A antagonist. Notable for a clinically significant food effect (oral absorption ~doubles… Oral half-life 7 h.
Atypical antipsychotic; potent D2 / 5-HT2A antagonist. Notable for a clinically significant food effect (oral absorption ~doubles with a ≥500 kcal meal) and QT prolongation (hERG block). Oral + IM (acute agitation).
PK: the oral row was real-PMID zero-content — PMID:10771448 states none of its four values. Re-cited to a review (PMID:11978164) for the two figures that exist: "half-life is approximately 6-7 hours" (the upper endpoint is stored) and "Oral bioavailability of ziprasidone taken with food is approximately 60%", which must be read as a FED value — fasting exposure is roughly half. The intramuscular row is re-sourced to PMID:15901743, 24 plus 12 healthy volunteers with a real intravenous arm, verbatim "The mean IM elimination t(1/2) was short and approximately 2.5 hours" and "bioavailability for the 5-mg IM ziprasidone dose was approximately 100%" — the stored 3 h was not stated and is not even the midpoint of the 2-5 h range its old citation gives. V 105 L on both rows and both absorption rates dropped as unsourced.
Pharmacokinetics
- Oral — t½ 7 h · F 60%
- Intramuscular — t½ 2.5 h · F 100%
Sources: PMID:10771448, PMID:16231965, PMID:9430133, PMID:12176106, PMID:9760039, PMID:12629531